Current efforts and the potential of nanomedicine in treating fungal keratitis

References

• Shukla PK, Kumar M, Keshava GB. Mycotic keratitis: an overview of diagnosis and therapy. Mycoses51(3), 183–199 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas PA. Current perspectives on ophthalmic mycoses. Clin. Microbiol. Rev.16(4), 730–797 (2003).
   PubMed Web of Science ®Google Scholar
• Galarreta DJ, Tuft SJ, Ramsay A, Dart JK. Fungal keratitis in London: microbiological and clinical evaluation. Cornea26(9), 1082–1086 (2007).
   PubMed Web of Science ®Google Scholar
• Bharathi MJ, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study. Indian J. Ophthalmol.51(4), 315–321 (2003).
   PubMedGoogle Scholar
• Carvalho ACA, Ruthes HI, Maia M et al. Ceratite fúngica no estado do Paraná- Brasil: aspectos epidemiológicos, etiológicos e diagnósticos. Rev. Iberoam. Micol.18(2), 76–78 (2001).
   PubMedGoogle Scholar
• Gopinathan U, Sharma S, Garg P et al. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Indian J. Ophthalmol.57(4), 273–279 (2009).
   PubMed Web of Science ®Google Scholar
• Panda A, Satpathy G, Nayak N, Kumar S, Kumar A. Demographic pattern, predisposing factors and management of ulcerative keratitis: evaluation of one thousand unilateral cases at a tertiary care centre. Clin. Experiment. Ophthalmol.35(1), 44–50 (2007).
   PubMed Web of Science ®Google Scholar
• Perez-Balbuena A, Vanzzini-Rosano V, Valadez-Virgen JD, Campos-Moller X. Fusarium keratitis in Mexico. Cornea28(6), 626–630 (2009).
   PubMed Web of Science ®Google Scholar
• Tanure MA, Cohen EJ, Sudesh S, Rapuano CJ, Laibson PR. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea19(3), 307–312 (2000).
   PubMed Web of Science ®Google Scholar
• Tuft SJ, Tullo AB. Fungal keratitis in the United Kingdom 2003–2005. Eye23(6), 1308–1313 (2009).
   PubMed Web of Science ®Google Scholar
• Ritterband DC, Seedor JA, Shah MK, Koplin RS, McCormick SA. Fungal keratitis at the New York Eye and Ear Infirmary. Cornea25(3), 264–267 (2006).
   PubMed Web of Science ®Google Scholar
• Xie LX, Zhong WX, Shi WY, Sun SY. Spectrum of fungal keratitis in north China. Ophthalmology113(11), 1943–1948 (2006).
   PubMed Web of Science ®Google Scholar
• Leck AK, Thomas PA, Hagan M et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br. J. Ophthalmol.86(11), 1211–1215 (2002).
   PubMed Web of Science ®Google Scholar
• Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in south India. Cornea21(6), 555–559 (2002).
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Vanini R, Ibrahim FM et al. Epidemiologic aspects and clinical outcome of fungal keratitis in southeastern Brazil. Eur. J. Ophthalmol19(3), 355–361 (2009).
   PubMedGoogle Scholar
• Thew MRJ, Todd B. Fungal keratitis in far north Queensland, Australia. Clin. Experiment. Ophthalmol.36(8), 721–724 (2008).
   PubMedGoogle Scholar
• Sirikul T, Prabriputaloong T, Smathivat A, Chuck RS, Vongthongsri A. Predisposing factors and etiologic diagnosis of ulcerative keratitis. Cornea27(3), 283–287 (2008).
   PubMedGoogle Scholar
• Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am. J. Ophthalmol.90(1), 38–47 (1980).
   PubMed Web of Science ®Google Scholar
• Upadhyay MP, Karmacharya PC, Koirala S et al. Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am. J. Ophthalmol.111(1), 92–99 (1991).
   PubMed Web of Science ®Google Scholar
• Khairallah SH, Byrne KA, Tabbara KF. Fungal keratitis in Saudi Arabia. Doc.Ophthalmol.79(3), 269–276 (1992).
   PubMed Web of Science ®Google Scholar
• Hagan M, Wright E, Newman M, Dolin P, Johnson G. Causes of suppurative keratitis in Ghana. Br J. Ophthalmol.79(11), 1024–1028 (1995).
   PubMed Web of Science ®Google Scholar
• Hall LR, Lass JH, Diaconu E, Strine ER, Pearlman E. An essential role for antibody in neutrophil and eosinophil recruitment to the cornea: B cell-deficient (microMT) mice fail to develop Th2-dependent, helminth-mediated keratitis. J. Immunol.163(9), 4970–4975 (1999).
   PubMedGoogle Scholar
• Kaur IP, Rana C, Singh H. Development of effective ocular preparations of antifungal agents. J. Ocul. Pharmacol. Ther.24(5), 481–493 (2008).
   PubMed Web of Science ®Google Scholar
• FlorCruz NV, Peczon I. Medical interventions for fungal keratitis. Cochrane Database Syst. Rev.1, CD004241 (2008).
   Google Scholar
• Srinivasan M. Fungal keratitis. Curr. Opin. Ophthalmol.15(4), 321–327 (2004).
   PubMedGoogle Scholar
• Thomas PA. Mycotic keratitis – an underestimated mycosis. J. Med. Vet. Mycol.32(4), 235–256 (1994).
   PubMedGoogle Scholar
• Wang LY, Sun ST, Jing Y, Han L, Zhang HM, Yue J. Spectrum of fungal keratitis in central China. Clin. Experiment. Ophthalmol.37(8), 763–771 (2009).
   PubMed Web of Science ®Google Scholar
• Godoy P, Cano J, Gene J, Guarro J, Hofling-Lima AL, Lopes CA. Genotyping of 44 isolates of Fusarium solani, the main agent of fungal keratitis in Brazil. J. Clin. Microbiol.42(10), 4494–4497 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas PA. Fungal infections of the cornea. Eye (Lond.)17(8), 852–862 (2003).
   PubMed Web of Science ®Google Scholar
• Salera CM, Tanure MAG, Lima WTM, Trindade FC, Moreira JA. Perfil das ceratites fúngicas no Hospital São Geraldo Belo Horizonte – MG. Arq. Bras. Oftalmol.65, 9–13 (2002).
   Google Scholar
• Alfonso EC, Miller D, Cantu-Dibildox J, O’Brien TP, Schein OD. Fungal keratitis associated with non-therapeutic soft contact lenses. Am. J. Ophthalmol.142(1), 154–155 (2006).
   PubMedGoogle Scholar
• Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin. Microbiol. Rev.13(4), 662–685 (2000).
   PubMed Web of Science ®Google Scholar
• Klotz SA, Au YK, Misra RP. A partial-thickness epithelial defect increases the adherence of Pseudomonas aeruginosa to the cornea. Invest. Ophthalmol. Vis. Sci.30(6), 1069–1074 (1989).
   PubMed Web of Science ®Google Scholar
• Ahearn DG, Zhang S, Stulting RD et al.Fusarium keratitis and contact lens wear: facts and speculations. Med. Mycol.46(5), 397–410 (2008).
   PubMed Web of Science ®Google Scholar
• Rao SK, Lam PTH, Li EYM, Yuen HKL, Lam DSC. A case series of contact lens-associated Fusarium keratitis in Hong Kong. Cornea26(10), 1205–1209 (2007).
   PubMedGoogle Scholar
• Chang DC, Grant GB, O’Donnell K et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA296(8), 953–963 (2006).
   PubMed Web of Science ®Google Scholar
• Gaujoux T, Chatel MA, Chaumeil C, Laroche L, Borderie VM. Outbreak of contact lens-related Fusarium keratitis in France. Cornea27(9), 1018–1021 (2008).
   PubMed Web of Science ®Google Scholar
• Khor WB, Aung T, Saw SM et al. An outbreak of Fusarium keratitis associated with contact lens wear in Singapore. JAMA295(24), 2867–2873 (2006).
   PubMed Web of Science ®Google Scholar
• Gorscak JJ, Ayres BD, Bhagat N et al. An outbreak of Fusarium keratitis associated with contact lens use in the northeastern United States. Cornea26(10), 1187–1194 (2007).
   PubMed Web of Science ®Google Scholar
• Granados JM, Puerto N, Carrilero MJ. Efficiency of voriconazole in fungal keratitis caused by Candida albicans. Arch. Soc. Esp. Oftalmol.79(11), 565–568 (2004).
   PubMedGoogle Scholar
• Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses52(3), 206–222 (2009).
   PubMed Web of Science ®Google Scholar
• Mendicute J, Orbegozo J, Ruiz M, Saiz A, Eder F, Aramberri J. Keratomycosis after cataract surgery. J. Cataract Refract. Surg.26(11), 1660–1666 (2000).
   PubMedGoogle Scholar
• Nayak N. Fungal infections of the eye: laboratory diagnosis and treatment. Nepal. Med. Coll. J.10(1), 48–63 (2008).
   PubMedGoogle Scholar
• Behrens-Baumann W. Topical antimycotics in ophthalmology. Ophthalmologica211(Suppl. 1), 33–38 (1997).
   PubMed Web of Science ®Google Scholar
• Ti SE, Scott A, Janardhanan P, Tan DTH. Therapeutic keratoplasty for advanced suppurative keratitis. Am. J. Ophthalmol.143(5), 755–762 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan XY, Wilhelmus KR, Matoba AY, Alexandrakis G, Miller D, Huang AJW. Pathogenesis and outcome of Paecilomyces keratitis. Am. J. Ophthalmol.147(4), 691–696 (2009).
   PubMed Web of Science ®Google Scholar
• Banitt M, Berenbom A, Shah M, Buxton D, Milman T. A case of polymicrobial keratitis violating an intact lens capsule. Cornea27(9), 1057–1061 (2008).
   PubMedGoogle Scholar
• Bashir G, Hussain W, Rizvi A. Bipolaris hawaiiensis keratomycosis and endophthalmitis. Mycopathologia167(1), 51–53 (2009).
   PubMedGoogle Scholar
• Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J. Am. Acad. Dermatol.30(5 Pt 1), 677–698 (1994).
   PubMed Web of Science ®Google Scholar
• Smith EB. History of antifungals. J. Am. Acad. Dermatol.23(4 Pt 2), 776–778 (1990).
   PubMed Web of Science ®Google Scholar
• Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am. J. Kidney Dis.31(5), 780–785 (1998).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs53(4), 539–549 (1997).
   PubMed Web of Science ®Google Scholar
• te Welscher YM, ten Napel HH, Balagué MM et al. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J. Biol. Chem.283(10), 6393–6401 (2008).
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science264(5157), 371–373 (1994).
   PubMed Web of Science ®Google Scholar
• O’Day DM, Ray WA, Head WS, Robinson RD. Influence of the corneal epithelium on the efficacy of topical antifungal agents. Invest. Ophthalmol. Vis. Sci.25(7), 855–859 (1984).
   PubMed Web of Science ®Google Scholar
• Loh AR, Hong K, Lee S, Mannis M, Acharya NR. Practice patterns in the management of fungal corneal ulcers. Cornea28(8), 856–859 (2009).
   PubMed Web of Science ®Google Scholar
• Lalitha P, Shapiro BL, Srinivasan M et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch. Ophthalmol.125(6), 789–793 (2007).
   PubMed Web of Science ®Google Scholar
• Xie LX, Zhai HL, Zhao J, Sun SY, Shi WY, Dong XG. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am. J. Ophthalmol.146(2), 260–265 (2008).
   PubMedGoogle Scholar
• O’Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr. Eye Res.5(11), 877–882 (1986).
   PubMed Web of Science ®Google Scholar
• Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J. Pharm. Sci.97(7), 2405–2425 (2008).
   PubMed Web of Science ®Google Scholar
• DiDomenico B. Novel antifungal drugs. Curr. Opin. Microbiol.2(5), 509–515 (1999).
   PubMed Web of Science ®Google Scholar
• Al Assiri A, Al Jastaneiah S, Al Khalaf A, Al Fraikh H, Wagoner MD. Late-onset donor-to-host transmission of Candida glabrata following corneal transplantation. Cornea25(1), 123–125 (2006).
   PubMedGoogle Scholar
• Levy J, Benharroch D, Peled N, Lifshitz T. Blastoschizomyces capitatus keratitis and melting in a corneal graft. Can. J. Ophthalmol.41(6), 772–774 (2006).
   PubMedGoogle Scholar
• Park KA, Ahn K, Chung ES, Chung TY. Pichia anomala fungal keratitis. Cornea27(5), 619–620 (2008).
   PubMedGoogle Scholar
• Khoo SH, Bond J, Denning DW. Administering amphotericin B: a practical approach. J. Antimicrob. Chemother.33(2), 203–213 (1994).
   PubMed Web of Science ®Google Scholar
• Kaushik S, Ram J, Brar GS, Jain AK, Chakraborti A, Gupta A. Intracameral amphotericin B: initial experience in severe keratomycosis. Cornea20(7), 715–719 (2001).
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Ture M, Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis. Cornea26(4), 398–402 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Valenzuela E, Song CD. Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis. Arch. Ophthalmol.123(12), 1721–1723 (2005).
   PubMedGoogle Scholar
• Gupta A, Srinivasan R, Kaliaperumal S, Saha I. Post-traumatic fungal endophthalmitis – a prospective study. Eye22(1), 13–17 (2008).
   PubMed Web of Science ®Google Scholar
• Koltin Y, Hitchcock CA. The search for new triazole antifungal agents. Curr. Opin. Chem. Biol.1(2), 176–182 (1997).
   PubMed Web of Science ®Google Scholar
• Foster CS, Stefanyszyn M. Intraocular penetration of miconazole in rabbits. Arch.Ophthalmol.97(9), 1703–1706 (1979).
   PubMed Web of Science ®Google Scholar
• Anderson RL, Carroll TF, Harvey JT, Myers MG. Petriellidium(Allescheria) boydii orbital and brain abscess treated with intravenous miconazole. Am. J. Ophthalmol.97(6), 771–775 (1984).
   PubMedGoogle Scholar
• Fitzsimons R, Peters AL. Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis. Am. J. Ophthalmol.101(5), 605–608 (1986).
   PubMed Web of Science ®Google Scholar
• Foster CS. Miconazole therapy for keratomycosis. Am. J. Ophthalmol.91(5), 622–629 (1981).
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsumoto Y, Takei K. The effects of intravenous miconazole on fungal keratitis. Am. J. Ophthalmol.98(4), 433–437 (1984).
   PubMedGoogle Scholar
• Zaidman GW. Miconazole corneal toxicity. Cornea10(1), 90–91 (1991).
   PubMedGoogle Scholar
• Galan A, Martin-Suarez EM, Gallardo JM, Molleda JM. Clinical findings and progression of 10 cases of equine ulcerative keratomycosis (2004–2007). Equine Vet. Educ.21(5), 236–242 (2009).
   Google Scholar
• Myers DA, Lsaza R, Ben Shlomo G, Abbott J, Plummer CE. Fungal keratitis in a gopher tortoise (Gopherus polyphemus). J. Zoo Wildl. Med.40(3), 579–582 (2009).
   PubMedGoogle Scholar
• Andrew SE, Brooks DE, Smith PJ, Gelatt KN, Chmielewski NT, Whittaker CJG. Equine ulcerative keratomycosis: visual outcome and ocular survival in 39 cases (1987–1996). Equine Vet. J.30(2), 109–116 (1998).
   PubMedGoogle Scholar
• Hemady RK, Chu W, Foster CS. Intraocular penetration of ketoconazole in rabbits. Cornea11(4), 329–333 (1992).
   PubMed Web of Science ®Google Scholar
• Therese KL, Bagyalakshmi R, Madhavan HN, Deepa P. In vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole and ketoconazole against ocular fungal isolates. Indian J. Med. Microbiol.24(4), 273–279 (2006).
   PubMedGoogle Scholar
• Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am. J. Ophthalmol.137(5), 820–825 (2004).
   PubMed Web of Science ®Google Scholar
• Manikandan P, Varga J, Kocsube S et al. Mycotic keratitis due to Aspergillus nomius. J. Clin. Microbiol.47(10), 3382–3385 (2009).
   PubMedGoogle Scholar
• Kredics L, Varga J, Kocsube S et al. Infectious keratitis caused by Aspergillus tubingensis. Cornea28(8), 951–954 (2009).
   PubMedGoogle Scholar
• Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced Fusarium keratitis progressing to endophthalmitis. Cornea22(4), 300–303 (2003).
   PubMed Web of Science ®Google Scholar
• Torres MA, Mohamed J, Cavazos-Adame H, Martinez LA. Topical ketoconazole for fungal keratitis. Am. J. Ophthalmol.100(2), 293–298 (1985).
   PubMedGoogle Scholar
• Zhang JJ, Wang LY, Gao CF, Zhang L, Xia HY. Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl β-cyclodextrin to rabbits. J. Ocul. Pharmacol. Ther.24(5), 501–506 (2008).
   PubMed Web of Science ®Google Scholar
• Behrens-Baumann W, Klinge B, Ruchel R. Topical fluconazole for experimental Candida keratitis in rabbits. Br. J. Ophthalmol.74(1), 40–42 (1990).
   PubMed Web of Science ®Google Scholar
• Chung PC, Lin HC, Hwang YS et al. Paecilomyces lilacinus scleritis with secondary keratitis. Cornea26(2), 232–234 (2007).
   PubMed Web of Science ®Google Scholar
• Sonego-Krone S, Sanchez-Di Martino D, Ayala-Lugo R et al. Clinical results of topical fluconazole for the treatment of filamentous fungal keratitis. Graefes Arch.Clin. Exp. Ophthalmol.244(7), 782–787 (2006).
   PubMed Web of Science ®Google Scholar
• Holgado S, Luna JD, Juarez CP. Postoperative Candida keratitis treated successfully with fluconazole. Ophthalmic Surg.24(2), 132 (1993).
   PubMedGoogle Scholar
• Sodhi PK, Mehta DK. Fluconazole in managment of ocular infections due to Curvularia. Ann. Ophthalmol.35(1), 68–72 (2003).
   Google Scholar
• Yilmaz S, Maden A. Severe fungal keratitis treated with subconjunctival fluconazole. Am. J. Ophthalmol.140(3), 454–458 (2005).
   PubMed Web of Science ®Google Scholar
• Su CY, Lin CP, Wang HZ et al. Intraocular use of fluconazole in the management of ocular fungal infection. Kaohsiung J. Med. Sci.15(4), 218–225 (1999).
   PubMedGoogle Scholar
• Avunduk AM, Beuerman RW, Warnel ED, Kaufman HE, Greer D. Comparison of efficacy of topical and oral fluconazole treatment in experimental Aspergillus keratitis. Curr. Eye Res.26(2), 113–117 (2003).
   PubMed Web of Science ®Google Scholar
• Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin. Infect. Dis.20(3), 657–664 (1995).
   PubMed Web of Science ®Google Scholar
• Abbasoglu OE, Hosal BM, Sener B, Erdemoglu N, Gursel E. Penetration of topical fluconazole into human aqueous humor. Exp. Eye Res.72(2), 147–151 (2001).
   PubMed Web of Science ®Google Scholar
• Li L, Wang Z, Li R, Luo S, Sun X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am. J. Ophthalmol.146(5), 724–728 (2008).
   PubMed Web of Science ®Google Scholar
• Fungtomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob. Agents Chemother.39(2), 295–300 (1995).
   PubMedGoogle Scholar
• Gonzalez G. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med. Mycol.47(1), 71–76 (2009).
   PubMed Web of Science ®Google Scholar
• Li LH, McCarthy P, Hui SW. High-efficiency electrotransfection of human primary hematopoietic stem cells. FASEB J.15(3), 586–588 (2001).
   PubMed Web of Science ®Google Scholar
• Qiu WY, Yao YF, Zhu YF et al. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis. Curr. Eye Res.30(12), 1113–1120 (2005).
   PubMed Web of Science ®Google Scholar
• Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother.31(1), 6–10 (1987).
   PubMed Web of Science ®Google Scholar
• Saracli MA, Erdem U, Gonlum A, Yildiran ST. Scedosporium apiospermum keratitis treated with itraconazole. Med. Mycol.41(2), 111–114 (2003).
   PubMed Web of Science ®Google Scholar
• Kalavathy CM, Parmar P, Kaliamurthy J et al. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea24(4), 449–452 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez-Ramos M, Claros B, Vale-Oviedo MA et al. Effect of the vehicle on the topical itraconazole efficacy for treating corneal ulcers caused by Aspergillus fumigatus. Clin. Experiment. Ophthalmol.36(4), 335–338 (2008).
   PubMedGoogle Scholar
• Yavas GF, Oztuerk F, Kusbeci T et al. Antifungal efficacy of voriconazole, itraconazole and amphotericin B in experimental Fusarium solani keratitis. Graefes Arch. Clin. Experiment. Ophthalmol.246(2), 275–279 (2008).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann. Pharmacother.31(4), 445–456 (1997).
   PubMed Web of Science ®Google Scholar
• Schelenz S, Goldsmith DJA. Aspergillus endophthalmitis: an unusual complication of disseminated infection in renal transplant patients. J. Infect.47(4), 336–343 (2003).
   PubMed Web of Science ®Google Scholar
• Tu EY, Park AJ. Recalcitrant Beauveria bassiana keratitis: confocal microscopy findings and treatment with posaconazole (noxafil). Cornea26(8), 1008–1010 (2007).
   PubMed Web of Science ®Google Scholar
• Amiel H, Chohan AAB, Snibson GR, Vajpayee R. Atypical fungal sclerokeratitis. Cornea27(3), 382–383 (2008).
   PubMed Web of Science ®Google Scholar
• Vyzantiadis TA, Kioumi A, Papadakis E et al. Rhino-cerebral zygomycosis resistant to antimycotic treatment: a case report. Mycoses52(1), 87–90 (2009).
   PubMedGoogle Scholar
• Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann. Pharmacother.34(9), 1032–1043 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36(5), 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother.41(3), 575–577 (1997).
   PubMed Web of Science ®Google Scholar
• Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am. J. Ophthalmol.143(1), 151–153 (2007).
   PubMed Web of Science ®Google Scholar
• Creti A, Esposito V, Bocchetti M et al. Voriconazole curative treatment for Acremonium species keratitis developed in a patient with concomitant Staphylococcus aureus corneal infection: a case report. In Vivo20(1), 169–171 (2006).
   PubMedGoogle Scholar
• Durand ML, Kim IK, D’Amico DJ et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am. J. Ophthalmol.140(3), 552–554 (2005).
   PubMed Web of Science ®Google Scholar
• Freda R. Use of oral voriconazole as adjunctive treatment of severe cornea fungal infection: case report. Arq. Bras. Oftalmol.69(3), 431–434 (2006).
   PubMedGoogle Scholar
• Kramer M, Kramer MR, Blau H et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology113(7), 1184–1186 (2006).
   PubMed Web of Science ®Google Scholar
• Al Badriyeh D, Leung L, Davies GE, Stewart K, Kong D. Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin. Ann. Pharmacother.43(6), 1139–1142 (2009).
   PubMedGoogle Scholar
• Tu EY. Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin. Cornea28(1), 116–119 (2009).
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol.122(1), 42–47 (2004).
   PubMed Web of Science ®Google Scholar
• Nulens E, Eggink C, Rijs AJ, Wesseling P, Verweij PE. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J. Clin. Microbiol.41(5), 2261–2264 (2003).
   PubMed Web of Science ®Google Scholar
• Klont RR, Eggink CA, Rijs AJMM, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin. Infect. Dis.40(12), E110–E112 (2005).
   PubMed Web of Science ®Google Scholar
• Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch. Ophthalmol.126(1), 18–22 (2008).
   PubMed Web of Science ®Google Scholar
• Lau D, Leung L, Ferdinands M et al. Penetration of 1% voriconazole eye drops into human vitreous humour: a prospective, open-label study. Clin. Experiment. Ophthalmol.37(2), 197–200 (2009).
   PubMed Web of Science ®Google Scholar
• Al Badriyeh D, Leung L, Roydhouse T et al. Prospective open-label study of the administration of two-percent voriconazole eye drops. Antimicrob. Agents Chemother.53(7), 3153–3155 (2009).
   PubMedGoogle Scholar
• Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am. J. Vet. Res.67(2), 296–301 (2006).
   PubMed Web of Science ®Google Scholar
• Shen YC, Wang MY, Wang CY et al. Clearance of intravitreal voriconazole. Invest. Ophthalmol.Vis. Sci.48(5), 2238–2241 (2007).
   PubMed Web of Science ®Google Scholar
• Hector RF. Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev.6(1), 1–21 (1993).
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann. Pharmacother.43(10), 1647–1657 (2009).
   PubMed Web of Science ®Google Scholar
• Cleary JD. Echinocandins: pharmacokinetic and therapeutic issues. Curr. Med. Res. Opin.25(7), 1741–1750 (2009).
   PubMed Web of Science ®Google Scholar
• Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob. Agents Chemother.49(4), 1359–1363 (2005).
   PubMed Web of Science ®Google Scholar
• Ozturk F, Yavas GF, Kusbeci T et al. Efficacy of topical caspofungin in experimental Fusarium keratitis. Cornea26(6), 726–728 (2007).
   PubMed Web of Science ®Google Scholar
• Vorwerk CK, Tuchen S, Streit F, Binder L, Hofmuller W, Behrens-Baumann W. Aqueous humor concentrations of topically administered caspofungin in rabbits. Ophthalmic Res.41(2), 102–105 (2009).
   PubMedGoogle Scholar
• Tawara S, Ikeda F, Maki K et al.In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother.44(1), 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Temesgen Z, Barreto J, Vento S. Micafungin: the newest echinocandin. Drugs Today.45(6), 469–478 (2009).
   PubMedGoogle Scholar
• Hiraoka T, Kaji Y, Wakabayashi T, Nanbu PN, Okamoto F, Oshika T. Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits. Cornea26(3), 336–342 (2007).
   PubMedGoogle Scholar
• Matsumoto Y, Dogru M, Goto E, Fujishima H, Tsubota K. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review. Cornea24(6), 748–753 (2005).
   PubMed Web of Science ®Google Scholar
• Hiraoka T, Wakabayashi T, Kaji Y et al. Toxicological evaluation of micafungin ophthalmic solution in rabbit eyes. J. Ocul. Pharmacol. Ther.21(2), 149–156 (2005).
   PubMedGoogle Scholar
• Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin. Drug Deliv.5(5), 567–581 (2008).
   PubMed Web of Science ®Google Scholar
• Schalenbourg A, Leys A, de Courten C, Coutteel C, Herbort CP. Corticosteroid-induced central serous chorioretinopathy in patients with ocular inflammatory disorders. Klin. Monbl. Augenheilkd.219(4), 264–267 (2002).
   PubMed Web of Science ®Google Scholar
• Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol.53(2), 139–149 (2008).
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today13(3–4), 135–143 (2008).
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol.136(5), 791–796 (2003).
   PubMed Web of Science ®Google Scholar
• Kredics L, Varga J, Kocsube S et al. Case of keratitis caused by Aspergillus tamarii. J. Clin. Microbiol.45(10), 3464–3467 (2007).
   PubMedGoogle Scholar
• Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J. Cataract Refract. Surg.33(9), 1546–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Yasueda S, Inada K, Matsuhisa K, Terayama H, Ohtori A. Evaluation of ophthalmic suspensions using surface tension. Eur. J. Pharm. Biopharm.57(2), 377–382 (2004).
   PubMed Web of Science ®Google Scholar
• Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems: recent advances. Prog. Retin. Eye Res.17(1), 33–58 (1998).
   PubMed Web of Science ®Google Scholar
• Giobbia M, Rossi MC, Conti E et al. Post-traumatic Aspergillus fumigatus keratitis. J. Mycol. Med.12(1), 32–33 (2002).
   Google Scholar
• Suzuki T, Hori N, Miyake T, Hori Y, Mochizuki K. Keratitis caused by a rare fungus, Malassezia restricta. Jpn. J. Ophthalmol.51(4), 292–294 (2007).
   PubMedGoogle Scholar
• Kovacs K, Stampf G, Klebovich I, Antal I, Ludanyi K. Aqueous solvent system for the solubilization azole compounds. Eur. J. Pharm. Sci.36(2–3), 352–358 (2009).
   PubMed Web of Science ®Google Scholar
• Esclusa-Diaz MT, Guimaraens-Mendez M, Perez-Marcos MB, Vila-Jato JL, Torres-Labandeira JJ. Characterization and in vitro dissolution behaviour of ketoconazole/β- and 2-hydroxypropyl-β-cyclodextrin inclusion compounds. Int. J. Pharm.143(2), 203–210 (1996).
   Google Scholar
• Owens PK, Fell AF, Coleman MW, Berridge JC. Complexation of voriconazole stereoisomers with neutral and anionic derivatised cyclodextrins. J. Incl. Phenom. Macrocycl. Chem.38(1–4), 133–151 (2000).
   Web of Science ®Google Scholar
• Cohen T, SauvageonMartre H, Brossard D et al. Amphotericin B eye drops as a lipidic emulsion. Int. J. Pharm.137(2), 249–254 (1996).
   Web of Science ®Google Scholar
• Wang CH, Wang WT, Hsiue GH. Development of polyion complex micelles for encapsulating and delivering amphotericin B. Biomaterials30(19), 3352–3358 (2009).
   PubMed Web of Science ®Google Scholar
• Brauninger GE, Shah DO, Kaufman HE. Direct physical demonstration of oily layer on tear film surface. Am. J. Ophthalmol.73(1), 132–134 (1972).
   PubMed Web of Science ®Google Scholar
• Nanjawade BK, Manvi FV, Manjappa AS. In situ forming hydrogels for sustained ophthalmic drug delivery. J. Control. Release122(2), 119–134 (2007).
   PubMed Web of Science ®Google Scholar
• Hirose H, Terasaki H, Awaya S, Yasuma T. Treatment of fungal corneal ulcers with amphotericin B ointment. Am. J. Ophthalmol.124(6), 836–838 (1997).
   PubMed Web of Science ®Google Scholar
• Delpalacio A, Perezblazquez E, Cuetara MS et al. Keratomycosis due to Scedosporium-apiospermum. Mycoses34(11–12), 483–487 (1991).
   PubMedGoogle Scholar
• Goldblum D, Frueh BE, Zimmerli S, Bohnke M. Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex. Cornea19(6), 853–856 (2000).
   PubMed Web of Science ®Google Scholar
• Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Expert Opin. Pharmacother.2(11), 1849–1857 (2001).
   PubMedGoogle Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci.87(12), 1479–1488 (1998).
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov. Today13(3–4), 144–151 (2008).
   PubMed Web of Science ®Google Scholar
• Wang W, Sasaki H, Chien DS, Lee VHL. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr. Eye Res.10(6), 571–579 (1991).
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev. Ind. Pharm.28(1), 1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev.59(6), 505–521 (2007).
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res.23(7), 1417–1450 (2006).
   PubMed Web of Science ®Google Scholar
• Hsu J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol.18(3), 235–239 (2007).
   PubMed Web of Science ®Google Scholar
• Calvo P, VilaJato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int. J. Pharm.153(1), 41–50 (1997).
   Web of Science ®Google Scholar
• Bin Choy Y, Park JH, Prausnitz MR. Mucoadhesive microparticles engineered for ophthalmic drug delivery. J. Phys. Chem. Solids69(5–6), 1533–1536 (2008).
   PubMed Web of Science ®Google Scholar
• Chiang CH, Tung SM, Lu DW, Yeh MK. In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J. Ocul. Pharmacol. Ther.17(6), 545–553 (2001).
   PubMed Web of Science ®Google Scholar
• Espuelas MS, Legrand P, Loiseau PM, Bories C, Barratt G, Irache JM. In vitro antileishmanial activity of amphotericin B loaded in poly(ε-caprolactone) nanospheres. J. Drug Target.10(8), 593–599 (2002).
   PubMed Web of Science ®Google Scholar
• Espuelas MS, Legrand P, Irache JM et al. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm.158(1), 19–27 (1997).
   Web of Science ®Google Scholar
• Sangeetha S, Venkatesh DN, Adhiyaman R, Santhi K, Suresh B. Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis. Trop. J. Pharm. Res.6(1), 653–659 (2007).
   Web of Science ®Google Scholar
• Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B–chitosan–dextran sulfate nanoparticles. Int. J. Pharm.329(1–2), 142–149 (2007).
   PubMed Web of Science ®Google Scholar
• Italia JL, Yahya MM, Singh D, Kumar MNVR. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm. Res.26(6), 1324–1331 (2009).
   PubMed Web of Science ®Google Scholar
• Ren TB, Xu N, Cao CH et al. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. J. Biomater. Sci. Polym. Ed.20(10), 1369–1380 (2009).
   PubMed Web of Science ®Google Scholar
• Amaral AC, Bocca AL, Ribeiro AM et al. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J. Antimicrob. Chemother.63(3), 526–533 (2009).
   PubMed Web of Science ®Google Scholar
• Peng HS, Liu XJ, Lv GX et al. Voriconazole into PLGA nanoparticles: improving agglomeration and antifungal efficacy. Int. J. Pharm.352(1–2), 29–35 (2008).
   PubMed Web of Science ®Google Scholar
• de Assis DN, Mosqueira VCF, Vilela JMC, Andrade MS, Cardoso VN. Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of (99m)technetium-fluconazole nanocapsules. Int. J. Pharm.349(1–2), 152–160 (2008).
   PubMedGoogle Scholar
• Rivera PA, Martinez-Oharriz MC, Rubio M, Irache JM, Espuelas S. Fluconazole encapsulation in PLGA microspheres by spray-drying. J. Microencapsul.21(2), 203–211 (2004).
   PubMed Web of Science ®Google Scholar
• Choi C, Jung H, Nam JP, Park Y, Jang MK, Nah JW. Preparation and characterization of deoxycholic acid-conjugated low molecular weight water-soluble chitosan nanoparticles for hydrophobic antifungal agent carrier. Polymer (Korea)33(4), 389–395 (2009).
   Google Scholar
• Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv. Ophthalmol.50(2), 167–182 (2005).
   PubMed Web of Science ®Google Scholar
• Mehanna MM, Elmaradny HA, Samaha MW. Ciprofloxacin liposomes as vesicular reservoirs for ocular delivery: formulation, optimization, and in vitro characterization. Drug Dev. Ind. Pharm.35(5), 583–593 (2009).
   PubMed Web of Science ®Google Scholar
• Bejjani RA, Jeanny JC, Bochot A, Behar-Cohen F. The use of liposomes as intravitreal drug delivery system. J. Fr. Ophtalmol.26(9), 981–985 (2003).
   PubMedGoogle Scholar
• Alghadyan AA, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposome-bound cyclosporine: clearance after intravitreal injection. Int. Ophthalmol.12(2), 109–112 (1988).
   PubMed Web of Science ®Google Scholar
• Barza M, Stuart M, Szoka F Jr. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest. Ophthalmol. Vis. Sci.28(5), 893–900 (1987).
   PubMed Web of Science ®Google Scholar
• Liu KR, Peyman GA, Khoobehi B, Alkan H, Fiscella R. Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. Ophthalmology94(9), 1155–1159 (1987).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J. Ocul. Pharmacol. Ther.16(6), 511–518 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Dhingra N, Velpandian T, Jaiswal J. Efficacy of fluconazole and liposome entrapped fluconazole for C. albicans induced experimental mycotic endophthalmitis in rabbit eyes. Acta Ophthalmol. Scand.78(4), 448–450 (2000).
   PubMedGoogle Scholar
• Habib FS, Fouad EA, Abdel-Rahman MS, Fathalla D. Liposomes as an ocular delivery system for fluconazole: in vivo study. Bull. Pharmaceut. Sci.31, 249–263 (2008).
   Google Scholar
• Kaji Y, Yamamoto E, Hiraoka T, Oshika T. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B. Graefes Arch. Clin. Experiment. Ophthalmol.247(4), 549–553 (2009).
   PubMed Web of Science ®Google Scholar
• Carrillo-Munoz AJ, Quindos G, Tur C et al. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemotherapy46(4), 235–244 (2000).
   PubMed Web of Science ®Google Scholar
• Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Ophthalmic Res.36(3), 172–176 (2004).
   PubMedGoogle Scholar
• Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis.10(8), 665–668 (1991).
   PubMed Web of Science ®Google Scholar
• De Logu A, Fadda AM, Pellerano ML, Diana G, Schivo ML. Prevention by L-α-phosphatidylcholine of antifungal activity in vitro of liposome-encapsulated imidazoles determined by using time–killing curves. Int. J. Antimicrob. Agents15(1), 43–48 (2000).
   PubMedGoogle Scholar
• Lee JW, Amantea MA, Francis PA et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother.38(4), 713–718 (1994).
   PubMed Web of Science ®Google Scholar
• Szoka FC Jr, Milholland D, Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother.31(3), 421–429 (1987).
   PubMed Web of Science ®Google Scholar
• Wasan KM, Brazeau GA, Keyhani A, Hayman AC, Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother.37(2), 246–250 (1993).
   PubMed Web of Science ®Google Scholar
• Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother.38(2), 223–227 (1994).
   PubMed Web of Science ®Google Scholar
• Singh M, Singh MP, Maiti SN, Gandhi A, Micetich RG, Atwal H. Preparations of liposomal fluconazole and their in vitro antifungal activity. J. Microencapsul.10(2), 229–236 (1993).
   PubMed Web of Science ®Google Scholar
• Hopfer RL, Mills K, Mehta R et al.In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother.25(3), 387–389 (1984).
   PubMed Web of Science ®Google Scholar
• Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery: liposomes versus lipid nanoparticles. Int. J. Nanomedicine2(4), 595–607 (2007).
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev.56(9), 1257–1272 (2004).
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev.54(Suppl. 1), S131–S155 (2002).
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm.242(1–2), 121–128 (2002).
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm.278(1), 71–77 (2004).
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J. Microencapsul.23(4), 377–388 (2006).
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. Rheological and in vitro release behaviour of clotrimazole-containing aqueous SLN dispersions and commercial creams. Pharmazie62(7), 505–509 (2007).
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. SLN and NLC for topical delivery of ketoconazole. J. Microencapsul.22(5), 501–510 (2005).
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. The use of SLN (R) and NLC (R) as topical particulate carriers for imidazole antifungal agents. Pharmazie61(5), 431–437 (2006).
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur RS. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy. Pak. J. Pharm. Sci.22(2), 131–138 (2009).
   PubMed Web of Science ®Google Scholar
• Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech10(1), 289–296 (2009).
   PubMed Web of Science ®Google Scholar
• Sanna V, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in vitro characterization, ex vivo and in vivo studies. J. Pharm. Pharmacol.59(8), 1057–1064 (2007).
   PubMed Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm.238(1–2), 241–245 (2002).
   PubMed Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Ali A, Aqil M. Gatifloxacin-loaded solid lipid nanoparticles for topical ocular delivery. J. Pharm. Pharmacol.61, A75 (2009).
   Google Scholar
• Niu M, Shi K, Sun Y, Wang J, Cui F. Preparation of CyA-loaded solid lipid nanoparticles and application on ocular preparations. J. Drug Deliv. Sci. Technol.18(4), 293–297 (2008).
   Web of Science ®Google Scholar
• Attama AA, Reichl S, Muller-Goymann CC. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res.34(8), 698–705 (2009).
   PubMed Web of Science ®Google Scholar
• Xu Y, Pang GR, Zhao DQ et al.In vitro activity of thimerosal against ocular pathogenic fungi. Antimicrob. Agents Chemother.54(1), 536–539 (2010).
   PubMedGoogle Scholar
• Iqbal NJ, Boey A, Park BJ, Brandt ME. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods. Diagn. Microbiol. Infect. Dis.62(3), 348–350 (2008).
   PubMed Web of Science ®Google Scholar
• Lalitha P, Vijaykumar R, Prajna NV, Fothergill AW. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. J. Clin. Microbiol.46(10), 3477–3478 (2008).
   PubMed Web of Science ®Google Scholar
• Oday DM, Ray WA, Robinson RD, Head WS. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin-B and natamycin. Invest. Ophthalmol. Vis. Sci.28(3), 596–603 (1987).
   PubMedGoogle Scholar
• Ikeda F, Saika T, Sato Y et al. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med. Mycol.47(2), 145–148 (2009).
   PubMed Web of Science ®Google Scholar
• Barasch A, Griffin AV. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol.3(3), 265–269 (2008).
   PubMed Web of Science ®Google Scholar
• Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J. Clin. Microbiol.44(12), 4342–4344 (2006).
   PubMed Web of Science ®Google Scholar